Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 2, 2012

Lorus Gains Genentech Patents for IL-17E in Cancer

  • Lorus Therapeutics entered into a global license agreement with Genentech for certain patents owned by Genentech related to anticancer agent IL-17E. Lorus has selected pancreatic cancer and malignant melanoma as the initial lead cancer indications for this agent.

    IL-17E (also known as IL-25) is a cytokine that plays an important role in inflammation. Lorus discovered that human IL-17E has potent anticancer properties against a range of solid tumors including melanoma, pancreatic, colon, lung, ovarian, and breast tumor models with very low toxicity. IL-17E is highly potent and does not require further modification or optimization before proceeding to the formal IND-enabling preclinical studies, according to the companies.

    "Lorus scientists were the first to discover the anticancer properties of IL-17E, and we have patents pending for the use of IL-17E in cancer in the major world markets,” notes Aiping Young, M.D., Ph.D., president and CEO of Lorus. “IL-17E represents a unique immunotherapeutic approach to the treatment of some of the most important cancers, and preclinical data to date shows excellent efficacy with low toxicity; properties that we plan to demonstrate in the clinic in the near future."

    The company has two antimicrobial programs at the preclinical phase and four cancer drug candidates besides IL-17E. LOR-2040 and Virulizin are both in Phase II trials. LOR-2040 targets RNR-R2 and is being studied as a treatment for AML. Virulizin is an immunotherapy being investigated against pancreatic cancer in collaboration with Zor Pharma. LOR-253 targets MTF-1 and is being testing in Phase I against solid tumors. LOR-500 targets MELK and is also being evaluated as a treatment for solid tumors at the lead optimization phase.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »